Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) are rising Friday after the San Diego-based biotech company shared a milestone regulatory update.
What To Know: Artiva said the Food and Drug Administration gave its AlloNK product fast track designation. It’s the first drug candidate in its category to receive this designation, giving it the potential to become the first to advance to a pivotal trial pending FDA feedback expected in the first half of next year.
